The historical standard of care for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) was chemotherapy plus a BCR::ABL1 tyrosine kinase inhibitor (TKI), followed by allogeneic stem cell transplant (alloSCT) in first remission [1]. Here, ABL1 is linked to acute lymphoblastic leukemia.